Baker Tilly Wealth Management’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-5,484
Closed -$557K 296
2025
Q4
$557K Hold
5,484
0.14% 147
2025
Q3
$300K Hold
5,484
0.07% 216
2025
Q2
$291K Hold
5,484
0.1% 186
2025
Q1
$237K Buy
5,484
+2
+0% +$101 0.09% 214
2024
Q4
$308K Sell
5,482
-2
-0% -$124 0.12% 185
2024
Q3
$374K Buy
5,484
+13
+0.2% +$734 0.17% 146
2024
Q2
$231K Sell
5,471
-137
-2% -$7.54K 0.09% 241
2024
Q1
$387K Buy
5,608
+13
+0.2% +$822 0.07% 305
2023
Q4
$414K Sell
5,595
-370
-6% -$24.3K 0.07% 327
2023
Q3
$407K Buy
+5,965
New +$506K 0.07% 304

Other funds holding EXAS

Baker Tilly Wealth Management's EXAS Position: Q1 2026 in Review

Baker Tilly Wealth Management sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 5,484 shares — an estimated $557K sold.

Baker Tilly Wealth Management first reported a position in EXAS in Q3 2023 and held it in 10 quarters. The position peaked at $557K in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Baker Tilly Wealth Management reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Baker Tilly Wealth Management sold 5,484 Exact Sciences shares in Q1 2026, an estimated $557K.
  • Baker Tilly Wealth Management first reported a position in Exact Sciences in Q3 2023 and held it in 10 quarters.
  • Baker Tilly Wealth Management's Exact Sciences position peaked at $557K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Baker Tilly Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.